Form 4: Crinetics Pharmaceuticals Executive Sells Shares Under 10b5-1 Plan
SEC Form 4
Dana Pizzuti, Chief Medical and Development Officer of Crinetics Pharmaceuticals, sold 5,000 shares of common stock on February 3, 2025, as part of a pre-arranged trading plan.
Summary
- Dana Pizzuti, the Chief Medical and Development Officer at Crinetics Pharmaceuticals, executed a transaction involving the company's common stock on February 3, 2025.
- Pizzuti exercised stock options to acquire 5,000 shares at a price of $16.89 per share.
- Simultaneously, Pizzuti sold 5,000 shares in the open market at a weighted average price of $39.07 per share, with prices ranging from $38.89 to $39.49.
- These transactions were conducted under a pre-arranged Rule 10b5-1 trading plan.
- Following these transactions, Pizzuti directly owns 31,748 shares of Crinetics Pharmaceuticals common stock and holds options for 119,042 shares.
Sentiment
Score: 5
Explanation: This is a routine disclosure of insider transactions. The use of a 10b5-1 plan suggests the sales were pre-planned and not based on any recent material non-public information. Therefore, the sentiment is neutral.
Positives
- The use of a 10b5-1 trading plan suggests that the sales were pre-planned and not based on insider information at the time of the transaction.
Industry Context
Form 4 filings are a routine part of the regulatory landscape for publicly traded companies, providing transparency into the transactions of company insiders. These filings are closely watched by investors seeking insights into management's perspective on the company's stock.
Comparison to Industry Standards
- Executive stock sales are common and are often part of compensation packages.
- The use of a 10b5-1 plan is a standard practice to avoid accusations of insider trading.
- Comparable companies also have executives who routinely file Form 4s related to stock options and sales.
Stakeholder Impact
- The sale of shares by a company executive could be perceived negatively by some investors, but the use of a 10b5-1 plan mitigates this concern.
Key Dates
| Date | Description |
|---|---|
| 09/30/2023 | 25% of the shares subject to the option vest |
| 02/03/2025 | Date of transaction: exercise of stock options and sale of shares. |
| 02/05/2025 | Date of Form 4 filing. |
| 10/10/2032 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.